Endothelin as a final common pathway in the pathophysiology of preeclampsia: Therapeutic implications

Current Opinion in Nephrology and Hypertension

Volumn 21, Issue 2, 2012, Pages 157-162

  George, Eric M ^a   Palei, Ana C ^a   Granger, Joey P ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

angiotensin type 1 receptor agonistic autoantibody; placental ischemia; soluble fms like tyrosine kinase 1; tumor necrosis factor ; vascular endothelial growth factor

Indexed keywords

ENDOTHELIN 1; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADAPTIVE IMMUNITY; ANTIANGIOGENIC ACTIVITY; ENDOTHELIAL DYSFUNCTION; HUMAN; IMMUNE RESPONSE; ISCHEMIA; NONHUMAN; PLACENTA DISORDER; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ADAPTIVE IMMUNITY; ANGIOGENESIS INHIBITORS; ENDOTHELIN-1; FEMALE; HUMANS; IMMUNITY, INNATE; ISCHEMIA; PLACENTA; PRE-ECLAMPSIA; PREGNANCY; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84857045909     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0b013e328350094b     Document Type: Review

References (45)

1. Roberts JM, Pearson G, Cutler J, Lindheimer M. Summary of the NHLBI Working Group on research on hypertension during pregnancy. Hypertension 2003; 41:437-445. (Pubitemid 36314613)
2. Lindheimer MD, Kanter D. Interpreting abnormal proteinuria in pregnancy: The need for a more pathophysiological approach. Obstet Gynecol 2010; 115 (2 Pt 1):365-375. This article highlights the limitations of proteinuria as a diagnostic in the preeclamptic patient, and highlights the need for new criteria to assess renal function in these patients.
3. Poon LC, Kametas NA, Chelemen T, et al. Maternal risk factors for hypertensive disorders in pregnancy: A multivariate approach. J Hum Hypertens 2010; 24:104-110. This study performs statistical analysis of a host of risk factors for preeclampsia to assemble a predictive model for preeclampsia screening.
4. Trogstad L, Magnus P, Stoltenberg C. Preeclampsia: Risk factors and causal models. Best Pract Res Clin Obstet Gynaecol 2011; 25:329-342. This article reviews the current literature and thoroughly examines the current evidence for statistically significant risk factors for the development of preeclampsia.
5. Duckitt K, Harrington D. Risk factors for preeclampsia at antenatal booking: Systematic review of controlled studies. BMJ 2005; 330:565.
6. Gaillard R, Steegers EA, Hofman A, Jaddoe VW. Associations of maternal obesity with blood pressure and the risks of gestational hypertensive disorders. The Generation R Study. J Hypertens 2011; 29:937-944. This study examined the correlation between maternal obesity and the risk of developing preeclampsia and gestational hypertension in a large cohort. Significant effects of high BMI were found for both disorders, highlighting the importance of maternal adiposity in the development of preeclampsia and gestational hypertension.
7. Walsh SW. Obesity: A risk factor for preeclampsia. Trends Endocrinol Metab 2007; 18:365-370. (Pubitemid 350137763)
8. Wolf M, Shah A, Lam C, et al. Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies. Am J Obstet Gynecol 2005; 193:16-22. (Pubitemid 40991821)
9. Knuist M, Bonsel GJ, Zondervan HA, Treffers PE. Risk factors for preeclampsia in nulliparous women in distinct ethnic groups: A prospective cohort study. Obstet Gynecol 1998; 92:174-178. (Pubitemid 28350843)
10. Bdolah Y, Lam C, Rajakumar A, et al. Twin pregnancy and the risk of preeclampsia: Bigger placenta or relative ischemia? Am J Obstet Gynecol 2008; 198:428e1-428e6.
11. ShembreyMA, Noble AD. An instructive case of abdominal pregnancy. Aust N Z J Obstet Gynaecol 1995; 35:220-221.
12. Hladunewich M, Karumanchi SA, Lafayette R. Pathophysiology of the clinical manifestations of preeclampsia. Clin J Am Soc Nephrol 2007; 2:543-549.
13. Brosens IA, Robertson WB, Dixon HG. The role of the spiral arteries in the pathogenesis of preeclampsia. Obstet Gynecol Annu 1972; 1:177-191.
14. Wu FT, Stefanini MO, Mac Gabhann F, et al. A systems biology perspective on sVEGFR1: Its biological function, pathogenic role and therapeutic use. J Cell Mol Med 2010; 14:528-552. This study exhaustively examines the available literature concerning the molecular mechanisms of sFlt-1 and makes a strong case for its importance in several disease states, including preeclampsia.
15. Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355:992-1005. (Pubitemid 44343543)
16. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111:649-658. (Pubitemid 36278583)
17. Bridges JP, Gilbert JS, Colson D, et al. Oxidative stress contributes to soluble fms-like tyrosine kinase-1 induced vascular dysfunction in pregnant rats. Am J Hypertens 2009; 22:564-568.
18. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349:427-434. (Pubitemid 36910021)
19. Gilbert JS, Verzwyvelt J, Colson D, et al. Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placental ischemia-induced hypertension. Hypertension 2010; 55:380-385. This study demonstrated that restoration of circulating free VEGF levels in rodents significantly improved renal function and hypertension in rats with placental ischemia. This highlights the importance of sFlt-1 in the disorder of placental ischemia, and suggests that restoration of VEGF might be a potential therapeutic in preeclampsia.
20. Bergmann A, Ahmad S, Cudmore M, et al. Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model. J Cell Mol Med 2010; 14:1857-1867.
21. Thadhani R, Kisner T, Hagmann H, et al. Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation 2011; 124:940-950. In this promising pilot study, Thadhani et al. removed circulating sFlt-1 from preeclamptic women by apheresis, resulting in improvements in hypertension, proteinuria, and time to delivery. This is the first study of sFlt-1 neutralization in humans and is a potentially powerful approach for the management of severe preeclampsia.
22. Conrad KP, Miles TM, Benyo DF. Circulating levels of immunoreactive cytokines in women with preeclampsia. Am J Reprod Immunol 1998; 40:102-111.
23. Greer IA, Lyall F, Perera T, et al. Increased concentrations of cytokines interleukin-6 and interleukin-1 receptor antagonist in plasma of women with preeclampsia: A mechanism for endothelial dysfunction? Obstet Gynecol 1994; 84:937-940. (Pubitemid 24360251)
24. LaMarca B, Speed J, Fournier L, et al. Hypertension in response to chronic reductions in uterine perfusion in pregnant rats: Effect of tumor necrosis factor-Alpha blockade. Hypertension 2008; 52:1161-1167.
25. Sunderland NS, Thomson SE, Heffernan SJ, et al. Tumor necrosis factor alpha induces a model of preeclampsia in pregnant baboons (Papio hamadryas). Cytokine 2011; 56:192-199. In this study, previous work in rodent and mouse models was verified in a nonhuman primate model. TNF-A infusion in baboons induced a preeclampsialike phenotype with endothelial dysfunction and maternal hypertension.
26. Cindrova-Davies T, Sanders DA, Burton GJ, Charnock-Jones DS. Soluble FLT1 sensitizes endothelial cells to inflammatory cytokines by antagonizing VEGF receptor-mediated signalling. Cardiovasc Res 2011; 89:671-679. Here an interesting study demonstrates a new link between sFlt-1 and the maternal immune response, showing that sFlt-1 heightens the endothelial dysfunction brought about inflammatory cytokines.
27. Wallukat G, Homuth V, Fischer T, et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest 1999; 103:945-952. (Pubitemid 29169601)
28. Dechend R, Viedt C, Muller DN, et al. AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase. Circulation 2003; 107: 1632-1639. (Pubitemid 36401560)
29. LaMarca B, Wallukat G, Llinas M, et al. Autoantibodies to the angiotensin type I receptor in response to placental ischemia and tumor necrosis factor alpha in pregnant rats. Hypertension 2008; 52:1168-1172.
30. Zhou CC, Ahmad S, Mi T, et al. Autoantibody from women with preeclampsia induces soluble Fms-like tyrosine kinase-1 production via angiotensin type 1 receptor and calcineurin/nuclear factor of activated T-cells signaling. Hypertension 2008; 51:1010-1019. (Pubitemid 351398948)
31. Zhou CC, Zhang Y, Irani RA, et al. Angiotensin receptor agonistic autoantibodies induce preeclampsia in pregnant mice. Nat Med 2008; 14:855-862.
32. Taylor RN, Varma M, Teng NN, Roberts JM. Women with preeclampsia have higher plasma endothelin levels than women with normal pregnancies. J Clin Endocrinol Metab 1990; 71:1675-1677. (Pubitemid 120032795)
33. Baksu B, Davas I, Baksu A, et al. Plasma nitric oxide, endothelin-1 and urinary nitric oxide and cyclic guanosine monophosphate levels in hypertensive pregnant women. Int J Gynaecol Obstet 2005; 90:112-117. (Pubitemid 40981947)
34. Nishikawa S, Miyamoto A, Yamamoto H, et al. The relationship between serum nitrate and endothelin-1 concentrations in preeclampsia. Life Sci 2000; 67:1447-1454. (Pubitemid 30658702)
35. Alexander BT, Kassab SE, Miller MT, et al. Reduced uterine perfusion pressure during pregnancy in the rat is associated with increases in arterial pressure and changes in renal nitric oxide. Hypertension 2001; 37:1191-1195. (Pubitemid 32304024)
36. Makris A, Thornton C, Thompson J, et al. Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. Kidney Int 2007; 71:977-984. (Pubitemid 46741987)
37. Abitbol MM, Ober MB, Gallo GR, et al. Experimental toxemia of pregnancy in the monkey, with a preliminary report on renin and aldosterone. Am J Pathol 1977; 86:573-590. (Pubitemid 8063539)
38. Alexander BT, Rinewalt AN, Cockrell KL, et al. Endothelin type a receptor blockade attenuates the hypertension in response to chronic reductions in uterine perfusion pressure. Hypertension 2001; 37 (2 Part 2):485-489. (Pubitemid 32199016)
39. Roberts L, LaMarca BB, Fournier L, et al. Enhanced endothelin synthesis by endothelial cells exposed to sera from pregnant rats with decreased uterine perfusion. Hypertension 2006; 47:615-618. (Pubitemid 43843885)
40. Murphy SR, LaMarca BB, Cockrell K, Granger JP. Role of endothelin in mediating soluble fms-like tyrosine kinase 1-induced hypertension in pregnant rats. Hypertension 2010; 55:394-398. This study demonstrates the importance of endothelin-1 as a link between increased sFlt-1 and maternal hypertension. Indeed, the hypertensive response brought about by increased sFlt-1 was completely blocked by an ETA antagonist, suggesting a possible therapeutic approach for the management of hypertension during preeclampsia.
41. LaMarca B, Parrish M, Ray LF, et al. Hypertension in response to autoantibodies to the angiotensin II type I receptor (AT1-AA) in pregnant rats: Role of endothelin-1. Hypertension 2009; 54:905-909.
42. Clouthier DE, Hosoda K, Richardson JA, et al. Cranial and cardiac neural crest defects in endothelin-A receptor-deficient mice. Development 1998; 125:813-824. (Pubitemid 28142824)
43. Taniguchi T, Muramatsu I. Pharmacological knockout of endothelin ET(A) receptors. Life Sci 2003; 74:405-409. (Pubitemid 37357070)
44. Olgun N, Patel HJ, Stephani R, et al. Effect of the putative novel selective ETAreceptor antagonist HJP272, a 1,3,6-trisubstituted-2-carboxy- quinol-4-one, on infection-mediated premature delivery. Can J Physiol Pharmacol 2008; 86:571-575.
45. Thaete LG, Neerhof MG, Silver RK. Differential effects of endothelin A and B receptor antagonism on fetal growth in normal and nitric oxide-deficient rats. J Soc Gynecol Invest 2001; 8:18-23. (Pubitemid 32157077)